Financial Data and Key Metrics Changes - Q3 revenue was $623 million, essentially flat compared to the same period last year, bringing year-to-date revenue to $1.84 billion [17] - The third quarter net loss was $28 million, an improvement driven by higher foreign exchange gains and the absence of a non-cash impairment charge recorded last year [17] - Adjusted diluted EPS was flat sequentially at $0.18, with changes attributed to the divestiture of ScholarOne [17] - Free cash flow was $115 million in Q3, totaling $276 million year-to-date, driven by adjusted EBITDA and working capital [22] Business Line Data and Key Metrics Changes - The A&G segment saw a 2% ACV growth, with a subscription mix now at 93% compared to 81% last year [7][8] - The Intellectual Property segment's recurring revenue was flat year-to-date, representing a 3% improvement in organic growth compared to the full year of 2024 [9] - Life Sciences and Health segment returned to 2% ACV growth, driven by new product introductions and AI integration [11] Market Data and Key Metrics Changes - The company secured over 100 contracts for its new content subscription framework, indicating strong market demand [8] - Renewal rates in Life Sciences and Health improved to 93%, up 100 basis points year-over-year [5] - The U.S. dollar remained weaker against foreign currencies, providing a foreign exchange tailwind on revenue [20] Company Strategy and Development Direction - The company is focused on executing its value creation plan, emphasizing product and AI development to drive organic growth [6][14] - Plans to streamline the business model and market focus include exiting A&G transactional books and the Life Sciences Real World Data Resell Market [15] - The company aims to enhance its core subscription and recurring revenue mix to improve predictability, achieving an 8% improvement this year compared to last year [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning the Intellectual Property segment to sustainable growth under new leadership [9][35] - The company anticipates continued acceleration in organic annual contract value and expects to raise revenue guidance by $50 million [24] - Management believes that operational efficiency and margin expansion will be achieved through the adoption of agentic AI [14] Other Important Information - The company has completed $150 million in share repurchases year-to-date and paid down $100 million in debt [5][23] - The strategic disposals are expected to lower revenue by approximately $90 million this year, with a similar impact anticipated next year [28] Q&A Session Summary Question: Insights on the patent renewal business and competitive landscape - Management noted that the patent and trademark renewal service declined by about 3% last year but is now flat year-to-date, with expectations for improvement under new leadership [35][36] Question: Updates on new innovations in the value creation plan - Management highlighted the introduction of AI-enabled products and a renewed focus on product innovation, with several new products expected to drive growth [41][42] Question: Impact of large ebook transactions on revenue and EBITDA - Management indicated that multiple large ebook transactions positively impacted revenue, with expectations for a decline in that area moving forward [47] Question: Potential of the business after strategic changes - Management expressed optimism about returning to market growth rates of 3-4% over time, citing strong fundamentals and a supportive customer base [48][49] Question: ACV acceleration and segment contributions - Management noted improvements across all segments, particularly in Life Sciences, with expectations for continued growth in the IP segment [55] Question: Trends in patents and trademarks - Management observed a gradual increase in patents in force and anticipated a recovery in volumes driven by innovation, particularly in AI [61][62] Question: Transactional revenues and their impact on guidance - Management explained that slower attrition of disposals contributed to improved revenue guidance, with a significant portion of revenue expected to decline next year [72]

Financial Data and Key Metrics Changes - Q3 revenue was $623 million, essentially flat compared to the same period last year, bringing year-to-date revenue to $1.84 billion [17] - The third quarter net loss was $28 million, an improvement driven by higher foreign exchange gains and the absence of a non-cash impairment charge recorded last year [17] - Adjusted diluted EPS was flat sequentially at $0.18, with changes attributed to the divestiture of ScholarOne [17] - Free cash flow was $115 million in Q3, totaling $276 million year-to-date, driven by adjusted EBITDA and working capital [22] Business Line Data and Key Metrics Changes - In the A&G segment, there was a 2% ACV growth, with a subscription mix now at 93% compared to 81% last year [7][8] - The Intellectual Property segment's recurring revenue was flat year-to-date, but showed a 3% improvement in organic growth rate compared to the full year of 2024 [9] - The Life Sciences and Health segment returned to 2% ACV growth, driven by new product introductions and AI integration [11] Market Data and Key Metrics Changes - The company secured over 100 contracts for its new content subscription framework, indicating strong market demand [8] - Renewal rates in the A&G segment were strong, with 90% of global subscriptions successfully renewed through October 27 [8] - The overall patents in force in core markets are expected to grow, indicating a potential recovery in the IP market [60] Company Strategy and Development Direction - The company is focused on executing its value creation plan, emphasizing product and AI development to drive organic growth [6][14] - There is a commitment to optimizing the business model by increasing the core subscription and recurring revenue mix [7] - The company is streamlining its business model by exiting non-core areas and focusing on strategic alternatives [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning the IP segment to sustainable growth under new leadership [9][34] - The company anticipates continued acceleration in organic annual contract value and recurring organic growth in the upper half of its guidance range [24] - There is optimism regarding the impact of AI on future growth, with expectations of a market recovery in the coming years [60] Other Important Information - The company has completed $150 million in share repurchases year-to-date and paid down $100 million in debt [5][23] - The company expects to maintain a balanced capital allocation strategy while investing in product innovation [30] Q&A Session Summary Question: Insights on the patent renewal business and competitive landscape - Management noted that the patent and trademark renewal service declined by about 3% last year but is now flat year-to-date, with expectations for improvement under new leadership [34] Question: Updates on the value creation plan and new innovations - Management highlighted the introduction of new AI-enabled products and a renewed focus on product innovation as key components of the value creation plan [42] Question: Impact of large ebook transactions on revenue and EBITDA - Multiple large ebook transactions positively impacted revenue in Q3, with expectations for a slower decline in disposals than previously anticipated [46][68] Question: Trends in the IP market and catalysts for recovery - Management indicated that the overall patents in force are expected to grow, with AI innovation likely to boost renewal volumes in the coming years [60] Question: AI initiatives and proprietary content - The majority of AI innovations support information services, with significant proprietary data being utilized to enhance product offerings [62]

Q3 2025 Earnings Call October 29, 2025 Safe Harbor Statement and Non-GAAP Financial Measures Forward-Looking Statements This communication includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, "forward-looking statements" within the meaning of the "safe harbor provisions" of the Private Securities Litigation Reform Act of 1995. These forward-looking statements c ...

Q2 2025 Earnings Call July 30, 2025 Safe Harbor Statement and Non-GAAP Financial Measures Forward-Looking Statements This communication includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, "forward-looking statements" within the meaning of the "safe harbor provisions" of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can ...

Core Insights - Clarivate Plc has launched DRG Commercial Analytics 360, a solution aimed at enhancing commercial performance for medtech companies by providing advanced insights into customer activity and market dynamics [1][2]. Group 1: Product Features - DRG Commercial Analytics 360 integrates the Procedure Finder's search capabilities with Clarivate's extensive provider and affiliations network, delivering real-world, data-driven intelligence [2]. - The platform enables precise omnichannel targeting, seamless integration, and intelligent bundling, allowing medtech companies to make data-driven decisions that improve patient access and business outcomes [3]. - The solution offers actionable intelligence by providing tailored insights into healthcare providers, their network affiliations, and the locations where procedures are performed [5]. Group 2: Market Impact - The platform categorizes procedures by type and eliminates code-level duplication, ensuring a reliable view of procedure volume and flow across the U.S. market [5]. - It provides 360-degree market visibility through modularized claims and code groupings, supporting accurate market sizing and informed resource allocation [5]. - Clarivate's data scientists apply tailored extrapolation methodologies to derive nuanced insights across various market segments, backed by expertise in medtech and U.S. healthcare [5].